Midatech Pharma ADR (MTP)

The current recommendation of Sell for MLP & Strategic Equity Fund (NASDAQ:MTP) is computed using the methods for investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking MTP has had from Portfolio Grader for 4 months.

MLP & Strategic Equity Fund (NASDAQ:MTP) ranks in the top 10% of its industry group, Biotechnology, and in the top 10% of its sector group, Health Care, with a market value of $36.9 billion. From an investment attractiveness vantage point, MTP is ranked squarely in the bottom quartile of the sector with a ranking of 638 among the 782 companies in the sector; the stock's Portfolio Grader ranking currently places it 279 among the 350 companies in this industry group, a position that is well below-average and number 3,833 in the 5000 company Portfolio Grader company universe.

MLP & Strategic Equity Fund (NASDAQ:MTP) is classified as a component of the 349 company Biotechnology GICS industry group, which is a segment of the 781 company GICS Health Care sector. The market value of MTP is $41.5 billion which falls in the top decile in its industry group. The stock's current Portfolio Grader ranking places it 266 among the 349 companies in this industry group, a spot that is well below-average; squarely in the bottom quartile of the sector with a ranking of 618 among the 781 companies in the sector, and number 3,808 in the nearly 5,000 company Portfolio Grader universe.

Portfolio Grader currently ranks MLP & Strategic Equity Fund (NASDAQ:MTP) a Sell. The methods for fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier researches and ranks nearly 5,000 stocks each week. The current Portfolio Grader recommendation on the shares has been in place for 3 months.

MLP & Strategic Equity Fund (NASDAQ:MTP) is a $40.9 billion in market value component of the Biotechnology GICS industry group where the current Portfolio Grader ranking for MTP puts it 273 among the 349 companies in this industry group, a position that is well below-average. MTP is ranked squarely in the bottom quartile of the sector with a ranking of 624 among the 782 companies in the sector and number 3,832 in the 5000 company Portfolio Grader company universe.

As one of the 785 companies in the GICS Health Care sector MLP & Strategic Equity Fund (NASDAQ:MTP) is a member of the 349 company Biotechnology GICS industry group within this sector. MTP has a market value of $42.7 billion which is in the top decile in its industry group. The stock's current Portfolio Grader ranking places it 272 among the 349 companies in this industry group, a position that is well below-average; squarely in the bottom quartile of the sector with a ranking of 622 among the 785 companies in the sector, and number 3,828 in the nearly 5,000 company Portfolio Grader universe.

Currently, MLP & Strategic Equity Fund (NASDAQ:MTP) has a Sell using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. MTP has maintained this ranking for 2 months.

MLP & Strategic Equity Fund (NASDAQ:MTP) is a member of the 345 company Biotechnology GICS industry group, which is part of the 782 company GICS Health Care sector. MTP's market value is $44.1 billion which falls in the top 10% of its industry group. The stock's current Portfolio Grader ranking places it 303 among the 345 companies in this industry group, a position that is well below-average; squarely in the bottom quartile of the sector with a ranking of 693 among the 782 companies in the sector, and number 4,218 in the nearly 5,000 company Portfolio Grader universe.

The current recommendation of Sell for MLP & Strategic Equity Fund (NASDAQ:MTP) is the result of using the system for investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking MTP has had from Portfolio Grader for 2 months.

Portfolio Grader currently ranks MLP & Strategic Equity Fund (NASDAQ:MTP) a Sell. Using Louis Navellier's investing methodology, this analytical tool researches stocks by employing proprietary fundamental and quantitative analytical tools. The current Portfolio Grader recommendation on the shares has been in place for the last month.